Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
Table 7
Expected healthcare costs (at 2010/2011 prices) over 2 years following first-line treatment with doxorubicin/ifosfamide combination and trabectedin monotherapy.
Resource
Expected healthcare costs per patient (Euros at 2010/2011 prices) over 2 years following first-line treatment
Italy
Spain
Sweden
Doxorubicin/ifosfamide
Trabectedin
Doxorubicin/ifosfamide
Trabectedin
Doxorubicin/ifosfamide
Trabectedin
Diagnosis
€634.4
(2%)
€634.4
(2%)
€1886.5
(6%)
€1886.5
(6%)
€2416.8
(7%)
€2416.8
(6%)
First-line cytotoxics
€2302.9
(6%)
€26885.4
(66%)
€1491.8
(5%)
€18432.1
(54%)
€3172.2
(9%)
€17934.5
(45%)
Second-line cytotoxics
€17007.3
(44%)
€2556.9
(6%)
€6524.1
(21%)
€1761.6
(5%)
€8469.5
(23%)
€3224.8
(8%)
Evaluations of response
€2025.7
(5%)
€1641.7
(4%)
€1280.4
(4%)
€1098.7
(3%)
€2758.0
(8%)
€2453.2
(6%)
Hospitalisations for chemotherapy infusion
€5093.0
(13%)
€3765.6
(9%)
€4704.7
(15%)
€3564.3
(10%)
€4326.8
(12%)
€3685.2
(9%)
Outpatient attendances for chemotherapy
€291.3
(<1%)
€338.0
(1%)
€560.9
(2%)
€423.4
(1%)
€998.6
(3%)
€439.0
(1%)
Tests before each cycle of chemotherapy
€212.5
(<1%)
€118.0
(<1%)
€266.2
(1%)
€197.9
(1%)
€244.3
(1%)
€217.0
(1%)
Pre- and postchemotherapy medication
€5706.9
(15%)
€1107.3
(3%)
€7621.1
(25%)
€1665.8
(5%)
€11732.4
(32%)
€7458.6
(19%)
Palliative care
€2918.9
(8%)
€1773.3
(4%)
€1942.7
(6%)
€1932.3
(6%)
€1200.9
(3%)
€1265.9
(3%)
Management of haematological toxicity
€2728.6
(7%)
€1811.1
(4%)
€4421.0
(14%)
€3233.7
(9%)
€1187.2
(3%)
€685.2
(2%)
Total
€38921.7
(100%)
€40631.7
(100%)
€30699.4
(100%)
€34196.3
(100%)
€36506.7
(100%)
€39780.2
(100%)
(Percentage of total expected cost is in parenthesis).
